leadf
logo-loader
viewAmryt Pharma PLC

Amryt Pharma PLC - Markus Ziener appointed as Non-Executive Director

RNS Number : 1349C
Amryt Pharma PLC
27 June 2016
 

 

 27 June, 2015

 

Amryt Pharma plc

("Amryt" or the "Company")

 

Markus Ziener appointed as Non-Executive Director

 

Amryt Pharma plc (AIM: AMYT, ESM: AYP), the clinical stage specialty pharma company focused on best in class treatments for orphan diseases, announces the appointment of Markus Ziener as Non-Executive Director with immediate effect. Mr Ziener is Chief Financial Officer of Software AG Stiftung. 

 

Mr Ziener joined Software AG Stiftung in 2013 as a Director of Asset Management becoming Chief Financial Officer in August 2014. Prior to joining Software AG Stiftung, a 20.9% shareholder in Amryt, Mr Ziener worked in a number of senior roles across a broad range of industries.

 

Harry Stratford, Chairman of Amryt, said "I am delighted to welcome Markus to the Board of Amryt.  As the Director of Asset Management within Software AG Stiftung, Markus has been a long term supporter of the Birken business and was Chairman of the Supervisory Board until the Company's recent acquisition by Amryt.  In this role, Markus was ultimately responsible for funding the development of our lead product, Episalvan, which has recently been approved in January by the European regulatory authorities for the treatment of partial thickness wounds.  Together with our existing Imlan product range and the opportunity to also develop Episalvan in the rare disease Epidermolysis Bullosa, we are particularly excited about the future potential for the Amryt business."

 

Additional Information required under the AIM rules for Companies:

 

The following information is disclosed under Schedule Two paragraph (g) of the AIM Rules.

 

(i)     Markus Ziener, 50, is currently a director of Software AG Stiftung.

 

(ii)    Within the last 5 years, he has also served as a director of the following companies:

 

Handelskontor Willmann für Naturprodukte GmbH

GeckoGroup AG

 

Markus Ziener has confirmed that there is no other additional information to be disclosed under Schedule Two paragraph (g) of the AIM Rules.

 

Enquiries:

 

Amryt Pharma plc

C/o FTI Consulting

Joe Wiley, CEO

Rory Nealon, CFO/COO




Shore Capital

+44 (0) 20 7408 4090

Nomad and Joint Broker


Bidhi Bhoma, Edward Mansfield




Davy

+353 (1) 679 6363

ESM Adviser and Joint Broker


John Frain, Anthony Farrell




Stifel

+44 (0) 20 7710 7600

Joint Broker


Jonathan Senior, Ben Maddison




FTI Consulting

+44 (0) 20 3727 1000

Simon Conway, Brett Pollard


 

 

About Amryt Pharma plc - see www.amrytpharma.com

 

Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or 'orphan' diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, propriety new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

 

Amryt's lead product, Episalvan®, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan® as a new treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. Amryt is currently planning a phase III study of Episalvan® in EB, which has been granted US and EU orphan drug designation.

 

Amryt's earlier stage products are focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need. These include acromegaly and Cushing's disease.

 

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEXLFLQQFZBBQ

Quick facts: Amryt Pharma PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt Pharma raises $40M in private placement from new and existing...

Amryt Pharma PLC (NASDAQ:AMYT) (LON:AMYT) CEO Joe Wiley tells Proactive the group has raised $40M from leading biotech investors in a private placement, with a tranche of the proceeds being used to in-license or invest in rare disease technologies. Wiley says investors include Stonepine...

on 9/12/20

4 min read